Toronto Dominion Bank Buys 171,652 Shares of Johnson & Johnson (JNJ)
Toronto Dominion Bank lifted its stake in Johnson & Johnson (NYSE:JNJ) by 12.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,501,583 shares of the company’s stock after acquiring an additional 171,652 shares during the quarter. Johnson & Johnson makes up approximately 0.6% of Toronto Dominion Bank’s investment portfolio, making the stock its 25th largest position. Toronto Dominion Bank owned approximately 0.06% of Johnson & Johnson worth $198,646,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in JNJ. Harding Loevner LP acquired a new position in Johnson & Johnson during the second quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. increased its position in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares during the last quarter. IHT Wealth Management LLC increased its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson during the second quarter worth approximately $124,000. 65.89% of the stock is currently owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE JNJ) traded up $0.39 during trading hours on Friday, hitting $142.04. The stock had a trading volume of 4,929,567 shares, compared to its average volume of 5,869,776. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35. The company has a market capitalization of $383,984.28, a PE ratio of 20.02, a PEG ratio of 2.90 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.68 earnings per share. analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.37%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.
A number of brokerages have weighed in on JNJ. Piper Jaffray Companies reissued a “hold” rating and set a $120.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research report on Monday, September 18th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research report on Wednesday, October 18th. UBS reissued a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a research report on Thursday, August 31st. Finally, Wells Fargo & Company upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $140.00 to $149.00 in a report on Monday, October 9th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $145.04.
TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/toronto-dominion-bank-buys-171652-shares-of-johnson-johnson-jnj/1765865.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.